A phase I–II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer
| Autor: | Syed A. Hussain, D. D. Moffitt, D. M. A. Wallace, D. R. Peake, Nicholas D. James, John Glaholm |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
Antimetabolites Antineoplastic medicine.medical_specialty Mitomycin medicine.medical_treatment Urology Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Invasiveness Aged Carcinoma Transitional Cell Chemotherapy Antibiotics Antineoplastic Bladder cancer Urinary bladder business.industry Hematology Middle Aged Prognosis medicine.disease Survival Analysis Chemotherapy regimen Surgery Radiation therapy Regimen Treatment Outcome medicine.anatomical_structure Transitional cell carcinoma Urinary Bladder Neoplasms Oncology Chemotherapy Adjuvant Female Radiotherapy Adjuvant Fluorouracil business Chemoradiotherapy Glomerular Filtration Rate |
| Zdroj: | Annals of Oncology. 12:929-935 |
| ISSN: | 0923-7534 |
| DOI: | 10.1023/a:1011133820532 |
| Popis: | Background: The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone. Synchronous chemotherapy regimens have yielded encouraging results in other primary sites. Patients and methods: Patients with T2 T4a N0/NX M0 bladder cancer were entered into this single centre phase I Il study. Patients received radiotherapy to 55 Gy in 20 fractions over four weeks. Concurrent chemotherapy was given with Mitomycin C 12 mg/m 2 day I and 5-fluorouracil 500 mg/m 2 / 24 hours weeks one and four of radiotherapy for five or seven days on each occasion. Results: Thirty-one patients entered the trial from March 1998 to December 1999 (22: 5-day; 9: 7-day schedule) Median age was 68 (range 58-79) years, 23 males and 8 females; T2: 9 (29%); T3a: 4 (12%): T3b: 9 (29%); T4: 9 (29%); TCC grade 2: 8 (26%) and grade 3: 23 (74%); 14 of 31 had hydronephrosis. Ten of thirty-one had a GFR < 50 ml/min. Toxicity was mild to moderate with the five-day schedule. More severe toxicity was seen with the seven-day schedule: five of nine patients failed to complete planned therapy. Pathological complete response rate at three months was 74% (5-day regimen) and 50% (7-day regimen). Overall 12-month survival was 65%. Conclusion: Chemoradiotherapy with the five-day schedule is feasible with acceptable toxicity in poor prognosis patients. A randomised trial is being launched. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|